Antimicrobial Therapy for Enterobacter cloacae Complex Infections
For carbapenem-susceptible Enterobacter cloacae complex infections, use carbapenems (meropenem or ertapenem) as first-line therapy; for carbapenem-resistant strains, use meropenem-vaborbactam or ceftazidime-avibactam based on in vitro susceptibility.
Treatment Algorithm Based on Resistance Profile
Non-ESBL-Producing, Carbapenem-Susceptible ECC
First-line: Carbapenems (meropenem or ertapenem)
- Meropenem is superior to β-lactam/β-lactamase inhibitor combinations (BLICs) for severe infections 1
- For meropenem, use prolonged infusion (3-hour) rather than 30-minute infusion to maximize bactericidal activity, particularly in high-inoculum infections 2
- BLICs may be considered only for non-severe infections with SOFA score ≤6.0 and confirmed ESBL-negative status 1
Avoid cefepime: Despite in vitro susceptibility, cefepime demonstrates poor clinical outcomes
- Cefepime-susceptible dose-dependent (SDD) isolates (MIC 4-8 μg/mL) have 71.4% mortality with cefepime versus 18.2% with carbapenems 3
- AmpC β-lactamase induction occurs rapidly with cefepime, leading to treatment failure even when initial MICs appear susceptible 2, 4
- Ertapenem shows initial activity but resistance emergence by 96 hours with 26-fold AmpC upregulation 2
ESBL-Producing ECC
First-line: Carbapenems (mandatory, not optional)
Alternative consideration: Ceftolozane-tazobactam has 67% susceptibility against ESBL-producing, AmpC-non-overexpressing strains 6, but clinical outcome data are limited
Carbapenem-Resistant ECC (CRE)
For severe infections:
Preferred: Meropenem-vaborbactam or ceftazidime-avibactam if active in vitro 7
- Meropenem-vaborbactam demonstrates consistent bactericidal activity (-3.6 to -4.6 log10 CFU/g) with stable MICs and minimal β-lactamase induction 2
- Ceftazidime-avibactam shows variable efficacy: bactericidal in some isolates but only bacteriostatic in others 2
- Do not use combination therapy if the isolate is susceptible to these newer agents 7
For metallo-β-lactamase producers resistant to all new agents:
For cefiderocol: Reserved for CRE resistant to ceftazidime-avibactam and meropenem-vaborbactam 7
For non-severe infections:
- Use older antibiotics based on individual susceptibility and infection source 7
- For complicated urinary tract infections: aminoglycosides (including plazomicin) preferred over tigecycline 7
Critical Pitfalls to Avoid
Never use tigecycline for bloodstream infections or pneumonia - it has poor outcomes in these settings 7
Avoid cefepime monotherapy even when susceptible by standard testing - AmpC induction leads to rapid resistance development and treatment failure 2, 3, 4
- Experimental mutants show 42% develop cefepime resistance and 99% develop piperacillin-tazobactam resistance through ampD mutations 4
Do not use carbapenem-based combination therapy for CRE unless meropenem MIC ≤8 mg/L and newer agents unavailable 7
Perform therapeutic drug monitoring (TDM) when using polymyxins, aminoglycosides, or carbapenems, especially in critically ill patients, those with organ dysfunction, or difficult-to-penetrate infection sites 8
Species-Specific Considerations
- Enterobacter xiangfangensis is the most common species (36% of isolates) 4
- Enterobacter hoffmannii presents the highest resistance rates to both β-lactams and non-β-lactams 4
- Cefepime nonsusceptibility particularly associated with E. hoffmannii ST78 and E. xiangfangensis ST93 carrying ESBLs 4
Antibiotic Stewardship Principles
Reserve newer β-lactam/β-lactamase inhibitor combinations (meropenem-vaborbactam, ceftazidime-avibactam, ceftolozane-tazobactam) for extensively resistant bacteria; avoid their use for carbapenem-susceptible strains 7. For non-severe infections with susceptible organisms, de-escalate to older agents based on susceptibility patterns once clinical stability achieved 7.